Acetaminophen; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Acetazolamide: Moderate Carbonic anhydrase inhibitors promote electrolyte excretion including hydrogen ions, sodium, and potassium. They can enhance the sodium depleting effects of other diuretics when used concurrently.
Pre-existing hypokalemia and hyperuricemia can also be potentiated by carbonic anhydrase inhibitors. Monitor serum potassium to determine the need for potassium supplementation and alteration in drug therapy. Acetohexamide: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus.
Acrivastine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Albiglutide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Because of this, a potential pharmacodynamic interaction exists between these drugs and all antidiabetic agents, including incretin mimetics.
This interference can lead to a loss of diabetic control, so diabetic patients should be monitored closely if these drugs are initiated. Alemtuzumab: Moderate Alemtuzumab may cause hypotension.
Careful monitoring of blood pressure and hypotensive symptoms is recommended especially in patients with ischemic heart disease and in patients on antihypertensive agents. Alendronate: Moderate When the intravenous formulation of alendronate is used for the treatment of hypercalcemia of malignancy, combination therapy with loop diuretics should be used with caution in order to avoid hypocalcemia.
In patients with hypercalcemia of malignancy, the initial treatment typically includes the use of loop diuretics, in combination with saline hydration, however, diuretic therapy should not be employed prior to correction of hypovolemia and dehydration. Alendronate; Cholecalciferol: Moderate When the intravenous formulation of alendronate is used for the treatment of hypercalcemia of malignancy, combination therapy with loop diuretics should be used with caution in order to avoid hypocalcemia.
Alfentanil: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with alfentanil. Aliskiren: Moderate Aliskiren can enhance the effects of loop-diuretics on blood pressure if given concomitantly.
This additive effect may be desirable, but dosages must be adjusted accordingly. Patients with hyponatremia or hypovolemia may also develop reversible renal insufficiency. Patients should be monitored for loss of effect of furosemide when aliskiren is initiated. Blood pressure and electrolytes should be routinely monitored. Aliskiren; Amlodipine: Moderate Aliskiren can enhance the effects of loop-diuretics on blood pressure if given concomitantly.
Aliskiren; Amlodipine; Hydrochlorothiazide, HCTZ: Moderate Aliskiren can enhance the effects of loop-diuretics on blood pressure if given concomitantly. Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Thus, use cautiously and with monitoring of renal function, blood pressure, cardiac status, electrolytes especially potassium , and monitor the clinical response for the condition treated.
Aliskiren; Hydrochlorothiazide, HCTZ: Moderate Aliskiren can enhance the effects of loop-diuretics on blood pressure if given concomitantly. Aliskiren; Valsartan: Moderate Aliskiren can enhance the effects of loop-diuretics on blood pressure if given concomitantly.
Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Hyponatremia or hypovolemia predisposes patients to acute hypotensive episodes following initiation of ACE inhibitor therapy. While ACE inhibitors and loop diuretics are routinely administered together in the treatment of heart failure, if an ACE inhibitor is to be administered to a patient receiving furosemide, initial doses should be conservative.
Alogliptin: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia.
Because of this, a potential pharmacodynamic interaction exists between furosemide and all antidiabetic agents, including alogliptin. This interference can lead to a loss of diabetic control, so diabetic patients should be monitored closely if this drug is initiated. Alogliptin; Metformin: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia.
Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Alogliptin; Pioglitazone: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Because of this, a potential pharmacodynamic interaction exists between furosemide and all antidiabetic agents.
Alpha-glucosidase Inhibitors: Minor Loop diuretics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Alprostadil: Minor The concomitant use of systemic alprostadil injection and antihypertensive agents, such as loop diuretics, may cause additive hypotension. Caution is advised with this combination. Systemic drug interactions with the urethral suppository MUSE or alprostadil intracavernous injection are unlikely in most patients because low or undetectable amounts of the drug are found in the peripheral venous circulation following administration.
In those men with significant corpora cavernosa venous leakage, hypotension might be more likely. Use caution with in-clinic dosing for erectile dysfunction ED and monitor for the effects on blood pressure. In addition, the presence of medications in the circulation that attenuate erectile function may influence the response to alprostadil. However, in clinical trials with alprostadil intracavernous injection, anti-hypertensive agents had no apparent effect on the safety and efficacy of alprostadil.
Aluminum Hydroxide; Magnesium Hydroxide: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Aluminum Hydroxide; Magnesium Hydroxide; Simethicone: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Amikacin: Moderate The risk of ototoxicity or nephrotoxicity secondary to aminoglycosides may be increased by the addition of concomitant therapies with similar side effects, including loop diuretics.
If loop diuretics and aminoglycosides are used together, it would be prudent to monitor renal function parameters, serum electrolytes, and serum aminoglycoside concentrations during therapy. Audiologic monitoring may be advisable during high dose therapy or therapy of long duration, when hearing loss is suspected, or in selected risk groups e.
Amiloride; Hydrochlorothiazide, HCTZ: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.
Aminoglycosides: Moderate The risk of ototoxicity or nephrotoxicity secondary to aminoglycosides may be increased by the addition of concomitant therapies with similar side effects, including loop diuretics. Amiodarone: Moderate Monitor serum electrolytes if coadministration of furosemide and amiodarone is necessary. Furosemide therapy may cause electrolyte abnormalities i.
Amlodipine; Benazepril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Amlodipine; Celecoxib: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.
Patients taking diuretics and NSAIDs concurrently are at higher risk of developing renal insufficiency. NSAIDs may reduce the natriuretic effect of diuretics in some patients. NSAIDs have been associated with an inhibition of prostaglandin synthesis, which may result in reduced renal blood flow leading to renal insufficiency and increases in blood pressure that are often accompanied by peripheral edema and weight gain.
Amlodipine; Olmesartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Amlodipine; Valsartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Amlodipine; Valsartan; Hydrochlorothiazide, HCTZ: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Amobarbital: Moderate Concurrent use of amobarbital with antihypertensive agents may lead to hypotension. Monitor for decreases in blood pressure during times of coadministration. Amoxicillin: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations.
This combination should be used with caution and patients monitored for increased side effects. Amoxicillin; Clarithromycin; Omeprazole: Moderate Proton pump inhibitors have been associated with hypomagnesemia. Hypomagnesemia occurs with loop diuretics furosemide, bumetanide, torsemide, and ethacrynic acid. Low serum magnesium may lead to serious adverse events such as muscle spasm, seizures, and arrhythmias. Therefore, clinicians should monitor serum magnesium concentrations periodically in patients taking a PPI and diuretics concomitantly.
Patients who develop hypomagnesemia may require PPI discontinuation in addition to magnesium replacement. Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations. Amoxicillin; Clavulanic Acid: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations. Amphetamine: Minor Amphetamine and Dextroamphetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics.
Close monitoring of blood pressure is advised. Amphetamine; Dextroamphetamine Salts: Minor Amphetamine and Dextroamphetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics.
Amphetamine; Dextroamphetamine: Minor Amphetamine and Dextroamphetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics.
Concurrent use of amphotericin B with loop diuretics can cause additive hypokalemia or hypomagnesemia due to renal potassium and magnesium wasting.
It is prudent to monitor renal function parameters and serum electrolyte concentrations during co-therapy with loop diuretics and drugs which induce hypokalemia. Amphotericin B: Moderate Amphotericin B-induced hypokalemia can result in interactions with other drugs. Ampicillin: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations. Ampicillin; Sulbactam: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations.
Amyl Nitrite: Moderate Concomitant use of nitrates with other antihypertensive agents can cause additive hypotensive effects. Dosage adjustments may be necessary. Angiotensin II receptor antagonists: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Angiotensin-converting enzyme inhibitors: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Apomorphine: Moderate Use of loop diuretics and apomorphine together can increase the hypotensive effects of apomorphine. Monitor blood pressure regularly during use of this combination. Apraclonidine: Minor Alpha blockers as a class may reduce heart rate and blood pressure.
While no specific drug interactions have been identified with systemic agents and apraclonidine during clinical trials, it is theoretically possible that additive blood pressure reductions could occur when apraclonidine is combined with the use of antihypertensive agents. Patients using cardiovascular drugs concomitantly with apraclonidine should have their pulse and blood pressure monitored periodically.
Aripiprazole: Minor Aripiprazole may enhance the hypotensive effects of antihypertensive agents. Arsenic Trioxide: Moderate Use caution when using arsenic trioxide concomitantly with loop diuretics, as these can cause electrolyte abnormalities, which can increase the risk of QT prolongation.
Articaine; Epinephrine: Moderate Loop diuretics may antagonize the pressor effects and potentiate the arrhythmogenic and hypokalemic effects of epinephrine. Asenapine: Moderate Secondary to alpha-blockade, asenapine can produce vasodilation that may result in additive effects during concurrent use of antihypertensive agents. The potential reduction in blood pressure can precipitate orthostatic hypotension and associated dizziness, tachycardia, and syncope.
If concurrent use of asenapine and antihypertensive agents is necessary, patients should be counseled on measures to prevent orthostatic hypotension, such as sitting on the edge of the bed for several minutes prior to standing in the morning and rising slowly from a seated position. Close monitoring of blood pressure is recommended until the full effects of the combination therapy are known. Aspirin, ASA; Butalbital; Caffeine; Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine.
Aspirin, ASA; Carisoprodol; Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. Aspirin, ASA; Oxycodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with oxycodone. Atenolol; Chlorthalidone: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.
Atracurium: Moderate Concomitant use of neuromuscular blockers and loop diuretics may prolong neuromuscular blockade, possibly due to hypokalemia or alterations in potassium concentrations across the end-plate membrane. While glucocorticoids with mineralocorticoid activity e.
Close monitoring of electrolytes should occur in patients receiving these drugs concomitantly. Azilsartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Azilsartan; Chlorthalidone: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Bacitracin: Minor Additive nephrotoxicity may occur with concurrent use of systemic bacitracin and other nephrotoxic agents. When possible, avoid concomitant administration of systemic bacitracin and other nephrotoxic drugs such as loop diuretics.
Topical administration of any preparation containing bacitracin, especially when applied to large surface areas, also should not be given with other drugs that have a nephrotoxic potential. Minor Additive nephrotoxicity may occur with concurrent use of these medicines.
When possible, avoid concomitant administration of systemic bacitracin and loop diuretics. Use of topically administrated preparations containing bacitracin, especially when applied to large surface areas, may have additive nephrotoxic potential with loop diuretics. Bacitracin; Hydrocortisone; Neomycin; Polymyxin B: Minor Additive nephrotoxicity may occur with concurrent use of systemic bacitracin and other nephrotoxic agents. Bacitracin; Polymyxin B: Minor Additive nephrotoxicity may occur with concurrent use of systemic bacitracin and other nephrotoxic agents.
Baclofen: Moderate Baclofen has been associated with hypotension. Concurrent use with baclofen and antihypertensive agents may result in additive hypotension. Dosage adjustments of the antihypertensive medication may be required.
Belladonna; Opium: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with opium. Benazepril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure.
Benazepril; Hydrochlorothiazide, HCTZ: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Bendroflumethiazide; Nadolol: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.
Benzhydrocodone; Acetaminophen: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with benzhydrocodone. Benzphetamine: Minor Benzphetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics.
Beta-agonists: Moderate Loop diuretics may potentiate hypokalemia and ECG changes seen with beta agonists. Hypokalemia due to beta agonists appears to be dose related and is more likely with high dose therapy. Caution is advised when loop diuretics are coadministered with high doses of beta agonists; potassium levels may need to be monitored.
Bisacodyl: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Bisoprolol; Hydrochlorothiazide, HCTZ: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Bosentan: Moderate Although no specific interactions have been documented, bosentan has vasodilatory effects and may contribute additive hypotensive effects when given with diuretics.
Brexpiprazole: Moderate Due to brexpiprazole's antagonism at alpha 1-adrenergic receptors, the drug may enhance the hypotensive effects of alpha-blockers and other antihypertensive agents.
Brompheniramine; Carbetapentane; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Brompheniramine; Dextromethorphan; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Brompheniramine; Guaifenesin; Hydrocodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Brompheniramine; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.
Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Brompheniramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Brompheniramine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Brompheniramine; Pseudoephedrine; Dextromethorphan: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Bupivacaine; Meloxicam: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.
Buprenorphine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with buprenorphine. Buprenorphine; Naloxone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with buprenorphine.
Butalbital; Acetaminophen; Caffeine; Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. Cabergoline: Moderate Cabergoline should be used cautiously with antihypertensive agents, including loop diuretics.
Cabergoline has been associated with hypotension. Initial doses of cabergoline higher than 1 mg may produce orthostatic hypotension. It may be advisable to monitor blood pressure. Cabozantinib: Minor Monitor for an increase in cabozantinib-related adverse reactions if coadministration with furosemide is necessary.
MRP2 inhibitors have the potential to increase plasma concentrations of cabozantinib; however, the clinical relevance of this interaction is unknown. Calcium Phosphate, Supersaturated: Moderate Concomitant use of medicines with potential to alter renal perfusion or function such as diuretics, may increase the risk of acute phosphate nephropathy in patients receiving sodium phosphate monobasic monohydrate; sodium phosphate dibasic anhydrous.
In addition, loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Canagliflozin: Moderate When canagliflozin is initiated, volume depletion may occur; some patients may have symptomatic hypotension. Before initiating canagliflozin assess volume status and correct any deficiency. In addition, loop diuretics can also decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose.
Monitor blood glucose, serum electrolytes, and volume status during concurrent use. Canagliflozin; Metformin: Moderate When canagliflozin is initiated, volume depletion may occur; some patients may have symptomatic hypotension. Candesartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Candesartan; Hydrochlorothiazide, HCTZ: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.
Capreomycin: Moderate The risk of ototoxicity or nephrotoxicity secondary to capreomycin may be increased by the addition of concomitant therapies with similar side effects, including loop diuretics. Ototoxicity from furosemide or other loop diuretics, while uncommon, can be a transient or permanent side effect of significance. Ototoxicity is best documented with the loop diuretics ethacrynic acid and furosemide, but may also occur with either bumetanide or torsemide. The exact mechanism by which furosemide or other loop diuretics produce ototoxicity is unknown.
Usually, reports indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, higher than recommended dosages or infusion rates, or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If loop diuretics and capreomycin are used together, it would be prudent to monitor renal function parameters, serum electrolytes, and serum aminoglycoside concentrations during therapy.
Captopril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Captopril; Hydrochlorothiazide, HCTZ: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure.
Carbenicillin: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations. Carbetapentane; Chlorpheniramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbetapentane; Diphenhydramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Carbetapentane; Guaifenesin; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbetapentane; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Carbetapentane; Phenylephrine; Pyrilamine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbetapentane; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbidopa; Levodopa: Moderate Concomitant use of antihypertensive agents with levodopa can result in additive hypotensive effects. Carbidopa; Levodopa; Entacapone: Moderate Concomitant use of antihypertensive agents with levodopa can result in additive hypotensive effects. Carbinoxamine; Dextromethorphan; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbinoxamine; Hydrocodone; Phenylephrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Carbinoxamine; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Carbinoxamine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Carbinoxamine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Cardiac glycosides: Moderate Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics, increasing the risk of proarrhythmic effects of cardiac glycosides. Potassium levels should be monitored and normalized prior to and during concurrent diuretic administration and these agents.
Cariprazine: Moderate Orthostatic vital signs should be monitored in patients who are at risk for hypotension, such as those receiving cariprazine in combination with antihypertensive agents. Atypical antipsychotics may cause orthostatic hypotension and syncope, most commonly during treatment initiation and dosage increases.
Patients should be informed about measures to prevent orthostatic hypotension, such as sitting on the edge of the bed for several minutes prior to standing in the morning, or rising slowly from a seated position.
Consider a cariprazine dose reduction if hypotension occurs. Casanthranol; Docusate Sodium: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Castor Oil: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives.
Cefaclor: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Clinicians should be aware that this may occur even in patients with minor or transient renal impairment.
Cefadroxil: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefazolin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefdinir: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefditoren: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefepime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefiderocol: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefixime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefoperazone: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefotaxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefotetan: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefoxitin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefpodoxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cefprozil: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftaroline: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftazidime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftazidime; Avibactam: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Ceftibuten: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftizoxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Ceftolozane; Tazobactam: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Ceftriaxone: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cefuroxime: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Celecoxib: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.
Cephalexin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cephalosporins: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cephalothin: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics.
Cephradine: Minor Nephrotoxicity associated with cephalosporins may be potentiated by concomitant therapy with loop diuretics. Cetirizine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Chlophedianol; Dexchlorpheniramine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chlophedianol; Guaifenesin; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chloral Hydrate: Major According to the manufacturer, coadministration of furosemide with chloral hydrate is not recommended.
Intravenous administration of furosemide within 24 hours of taking chloral hydrate has resulted in flushing, sweating, restlessness, nausea, increased blood pressure, and tachycardia in isolated cases. Chloroprocaine: Moderate Local anesthetics may cause additive hypotension in combination with antihypertensive agents. Chlorothiazide: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.
Chlorpheniramine; Codeine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when a loop diuretic is administered with codeine. Chlorpheniramine; Dextromethorphan; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Chlorpheniramine; Dextromethorphan; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chlorpheniramine; Dihydrocodeine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Chlorpheniramine; Dihydrocodeine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.
Chlorpheniramine; Guaifenesin; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.
Chlorpheniramine; Hydrocodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Chlorpheniramine; Hydrocodone; Phenylephrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Your free 1 year of online access expired. Log in to Davis's Drug Guide.
Forgot Your Password? Enter your username below and we'll send you an email explaining how to change your password. Note: Your username may be different from the email address used to register your account. Forgot Your Username? Enter your email below and we'll resend your username to you. Contact Support If you need further assistance, please contact Support.
Remember Me. Forgot your username or password? Purchase a subscription. A Davis's Drug Guide subscription is required to. Already have an account? Log In. Please contact me in response to this feedback. Email Phone Best time to call:. My instructor asked me point blank "what is the reason to give an iv push med slowly.
I know it probably depends on the med itself, but in general, can anyone answer what happens when an iv med is given too fast? Thanks so much,. Apr 27, Typically depends on the drug, for instance pushing IV Ativan rapidly can cause cardiac arrest, pushing IV Dilaudid, Morpine, or Fentanyl rapidly increases the risk of respiratory depression and sedation. Also cardiac drugs such as Lopressor or Cardizem should be pushed over 5 minutes except during a code situation or other wise specified by MD slamming these types of drugs can cause serious cardiac dysrhythmias and cardiac arrest.
I also always push IV Lasix slowly because if pushed rapidly it can cause deafness. Before administering any drug you're unfamiliar with always consult your drug book, charge nurse, or pharmacist on staff. Hope this helps! Has 32 years experience. Apr 28, I think your instructor was looking for the term "speed shock".
0コメント